Author

Hamida Umar

Observed name: H. Umar

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University

Observed institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University

OpenAlex ID: A5087740258

Phase I study of neoadjuvant 5-fluorouracil (5FU) chemoradiation (CRT) and trametinib in patients with locally advanced rectal cancers (LARC).

2017 · Christina Sing-Ying Wu, Terence M Williams, et al. · Journal of Clinical Oncology · 2

Phase I study of trametinib with neoadjuvant chemoradiation (CRT) in patients with locally advanced rectal cancers (LARC).

2017 · Christina Sing-Ying Wu, Terence Marques Williams, et al. · Journal of Clinical Oncology · 1

Phase 1 Study of Trametinib and Neoadjuvant Chemoradiation (CRT) in Locally Advanced Rectal Cancer (LARC) with KRAS, BRAF, or NRAS Mutations

2016 · E.J. Wuthrick, T.M. Williams, et al. · International Journal of Radiation Oncology*Biology*Physics

Phase I study of trametinib and neoadjuvant chemoradiation (CRT) in patients with locally advanced rectal cancers (LARC) that harbor KRAS, BRAF, or NRAS mutations.

2016 · Christina Sing-Ying Wu, Terence Marques Williams, et al. · Journal of Clinical Oncology

Works count: 4

Citation count: 3

H-index: 1

I10-index: